Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 28, 2025
Subject: Regulatory milestone for depemokimab, an ultra-long-acting biologic targeting interleukin-5 (IL-5).
Key Financial Metrics
This filing is a current report regarding a regulatory development and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Developments
The primary material change is the acceptance by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA) for depemokimab. Key developments include:
- Indications: Add-on maintenance treatment for asthma with type 2 inflammation (adults and adolescents 12+) and chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.
- Dosing Advantage: If approved, depemokimab will be the first ultra-long-acting biologic with a 6-month (26-week) dosing regimen, requiring only two injections per year.
- Clinical Evidence:
- SWIFT-1 and SWIFT-2 (Asthma): Showed reduced exacerbation and hospitalisation rates as add-on therapy.
- ANCHOR-1 and ANCHOR-2 (CRSwNP): Showed reduced nasal polyp size and obstruction compared to placebo.
Outlook, Risks, and Management Commentary
Management Commentary: Kaivan Khavandi, SVP Global Head of Respiratory/Immunology R&D, stated that simultaneous submissions highlight confidence in depemokimab to reduce the burden of asthma and CRSwNP. The drug targets IL-5, a key driver of type 2 inflammation, offering sustained inhibition with improved patient adherence due to longer dosing intervals.
Pipeline Status: Depemokimab is currently not approved in any country. Additional Phase III trials are ongoing for eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES).
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2023 Form 20-F and Q3 2024 results, including regulatory approval uncertainties.
Investor Verification Checklist
- Confirm the final approval decision and timeline from the EMA for depemokimab.
- Verify the commercial launch strategy and pricing for a 6-month dosing biologic in the respiratory market.
- Monitor the results of the NIMBLE study regarding switching patients from mepolizumab or benralizumab to depemokimab.
- Review the full safety data from ANCHOR-1 and ANCHOR-2 when presented at the upcoming scientific congress.
- Assess the competitive landscape for IL-5 inhibitors in asthma and CRSwNP.